In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Sell rating on First Advantage (FA – Research Report), with a price target of $35.00. The company’s shares opened today at $13.34.
Kumar covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Apellis Pharmaceuticals, and Reata Pharmaceuticals. According to TipRanks, Kumar has an average return of 16.9% and a 50.29% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for First Advantage with a $18.08 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $15.89 and a one-year low of $10.07. Currently, First Advantage has an average volume of 312.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
The company is a risk mitigation and business solutions provider. It operates in six primary business segments: Lender Services, Data Services, Dealer Services, Employer Services, Multifamily Services and Investigative & Litigation Support Services.
Read More on FA:
- First Advantage Reports First Quarter 2023 Results
- First Advantage Announces Release of 2023 Annual Trends Report
- First Advantage introduces latest innovations to streamline screening processes
- First Advantage Introduces Latest Innovations Designed to Streamline Screening Processes and Improve Applicant Experiences
